Licensing status

Publication and contact information

Infectious disease


Ebola glycoprotein GP1; Ebola glycoprotein GP2

Nonhuman primate studies suggest a cocktail of three mAbs called MB-003, which targets GP1 and GP2, could treat Ebola infection. In nonhuman primates showing symptoms of Ebola infection, MB-003 given in 3 doses 120, 170 and 250 hours after exposure resulted in survival in 3 of 7 animals. Next steps include dose optimization, pharmacology and toxicology testing.
MB-003 is in preclinical development to treat Ebola infection.

SciBX 6(36); doi:10.1038/scibx.2013.996
Published online Sept. 19, 2013

Patented by the U.S. Army Medical Research Institute of Infectious Diseases; licensed to Mapp Biopharmaceutical Inc.; available for licensing and partnering through Mapp

Pettitt, J. et al. Sci. Transl. Med.; published online Aug. 21, 2013;
Contact: Gene G. Olinger, U.S. Army Medical Research Institute of Infectious Diseases, Frederick, Md.
Contact: Larry Zeitlin, Mapp Biopharmaceutical Inc.,
San Diego, Calif.